The objective of the current study was therefore to assess real‐world efficacy of crizotinib in patients with ALK‐positive NSCLC and to identify the factors associated with PFS and overall survival (OS) after crizotinib initiation in regular clinical practice, especially in South Korea. The gene discussed is ALK; the disease is non-small cell lung carcinoma.